Value of Treatment: 1st Round

On 22 June 2017, the two-year EBC research project on the “Value of Treatment of Brain Disorders (VoT) in Europe” came to a close with the launch of a policy white paper including the data collected by 9 expert working groups.

Covering a range of mental and neurological disorders, the VoT study examined health gains and socio-economic impacts of best health interventions (pharmacological and psychosocial alike), and addressed the current early diagnosis and the treatment gap of the various brain disorders.

VoT wanted to explore bridging the early diagnosis and treatment gap, as despite the escalating costs of brain disorders, numerous needs of individuals at risk and patients are unmet, and around 8 out of 10 people living with a brain disorder remain non-treated or inadequately treated although effective treatments exist. Health services, generally, remain quite fragmented, and working groups collectively found that more patient-centred and seamless, interdisciplinary care is still needed. Furthermore, though there has been significant progress in brain research over the last 50 years, and basic and translational research are at a threshold for new findings with a major impact on treatment, continued investment into brain research remains as important and necessary as ever.

The conference, held under the auspices of the Maltese EU Presidency, focused on addressing the burden of diseases and issues in the current health care system, the health services delivery and care pathways design and proposing evidence-based and cost-effective solutions to achieve high value for patients.

Keynote speakers at the conference included Mr Martin Seychell, Deputy Director-General, Directorate General for Health and Food Safety, European Commission and Dr Line Matthiessen, Acting Director, Health Directorate, Directorate General for Research & Innovation, European Commission, as well as a panel of various experts from organisations like the European Commission, European Parliament, Organisation for Economic Co-operation and Development (OECD) and European Observatory on Health Systems and Policies discussed the policy recommendations provided in the White Paper, and views by patient and carer advocates such as The European Federation of Families of People with Mental Illness (EUFAMI) and AGE Platform Europe gave depth to the conclusions found by the two-year study.

With the completion of the first VoT project, EBC provided the necessary policy recommendations to address the treatment gap and its consequences for patients and citizens at large.

Overarching scientific publications

  • EuroHealth Journal (January 2018)
  • WHO Bulletin (May 2018)
  • European Journal of Neurology (ongoing)

Individual scientific publications

  • European Psychiatry (Schizophrenia)
  • European Journal of Epilepsy

The value of treatment policy white paper: towards optimizing research and care for brain disorders. Brussels: European Brain Council; 2017. Available here.

All published documents can now be read:

Discussion Paper 1
Discussion Paper 2
Policy white paper

Throughout the project, case study analyses have been conducted for the following disorders. Follow the individual links below to read more about each case study, and study the results of each disorder.

Alzheimer’s Disease – Posters / Report
Multiple Sclerosis
Normal-pressure hydrocephalus (NPH)
Parkinson’s disease
Restless Legs Syndrome
Full poster booklet

Project Video:

The Value of Treatment (VoT) project is supported through financial contributions from:

Biogen, BMS-Pfizer Alliance, Boehringer Ingelheim GmbH, Grunenthal, Janssen, Livanova, Lundbeck, Medtronic, MSD, Novartis, Pfizer, Roche, Takeda, TEVA Pharmaceuticals, UCB Biopharma, Vifor Pharma, EARLS and EURLSSG.

Back to project homepage